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Letters to the Editor
Cardiac Resynchronization Therapy,
Central Sleep Apnea, and Cheyne-Stokes
Respiration in Chronic Heart Failure Patients
We congratulate Sinha et al. (1) for their interesting and innova-
tive report in JACC on the therapeutic effect of biventricular pacing
on central sleep apnea (CSA). A few questions remain: the title
suggests some information about Cheyne-Stokes respiration
(CSR), which is not equivalent to CSA; however, results are
lacking. Were all apnea/hypopnea events central in nature or did
some also have obstructive or mixed events? Completely blinded
serial scoring is difficult in patients undergoing an intervention
such as an implantation device, and therefore a bias in visual
scoring might be possible. We would be interested in learning
some additional objective values such as desaturation index or time
in apnea. This would be of greater value than minimum SaO2 in
their Table 3.
In their discussion, the investigators state that CSA is related to
heart failure, a statement that contrasts to similar findings on
exercise and echocardiography in both groups. In view of this, how
do the researchers explain the dramatic effects of cardiac resyn-
chronization therapy (CRT) on CSA when the benefit of CRT (on
echocardiography and exercise) is equal in patients with and
without CSA? Moreover, the effect of CRT on sleep apnea, as
described by Sinha et al. (1), is huge and much higher than in our
experience and even higher than after cardiac transplantation (2,3).
In these reports, cyclic respiration/CSR was abolished, but sleep
apnea persisted or got worse in a considerable number of patients.
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REPLY
We thank Dr. Scharf and colleagues for their valuable comments
to our study on central sleep apnea (CSA) and cardiac resynchro-
nization therapy (CRT) (1). Importantly, all patients in our study
had CSA and no evidence of obstructive sleep apnea (OSA).
Because apnea occurred with a periodic pattern in patients with
known advanced heart failure we believe that the breathing pattern
can be classified as CSA although timing of arousals relative to
respiratory events could not be evaluated with the polygraphy
system used. We agree that desaturation index, breathing cycle
length, and time in apnea add important information and have
summarized these data in Table 1.
We have now studied more patients with mixed apnea or OSA
and found less improvement in mixed apnea and no significant
effect in OSA (2). Therefore, we believe that CRT works mainly
on CSA by improving cardiac hemodynamics.
The notion that CSA is related to the severity of heart failure
was derived from previous studies (3) and not from our data. We
caution that our results refer to a small group of patients with short
Table 1. Additional Parameters Obtained by Polygraphy Before
and During CRT
Pre-CRT On CRT p Value
Desaturation index 23  10.6 9.6  5 0.002
Cycle length (s) 60.6  5.7 45.8  2.2 0.002
Ventilation/apnea length
ratio
1.15  0.12 0.42  0.1 0.001
CRT  cardiac resynchronization therapy.
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